SPDR S&P Biotech ETF
732 hedge funds and large institutions have $9.85B invested in SPDR S&P Biotech ETF in 2024 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 193 increasing their positions, 280 reducing their positions, and 115 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
24% less funds holding in top 10
Funds holding in top 10: 21 → 16 (-5)
31% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 280
38% less call options, than puts
Call options by funds: $2.07B | Put options by funds: $3.32B
Holders
732
Holding in Top 10
16
Calls
$2.07B
Puts
$3.32B
Top Buyers
| 1 | +$799M | |
| 2 | +$306M | |
| 3 | +$197M | |
| 4 |
Morgan Stanley
New York
|
+$194M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$164M |
Top Sellers
| 1 | -$384M | |
| 2 | -$366M | |
| 3 | -$287M | |
| 4 |
CI Investments Inc
Toronto,
Ontario, Canada
|
-$96.4M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$80.7M |